MedTrace Logo

A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis

NCT02469467 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-02-08

No results posted yet for this study

Summary

The purpose is to evaluate the tolerability, safety and efficacy of VS-505 when given with meal for 8 weeks to hemodialysis patients with hyperphosphatemia

Conditions

Interventions

DIETARY_SUPPLEMENT

VS-505

VS-505 is orally administered with meal for 8 weeks

Sponsors & Collaborators

  • KDL Inc.

    lead INDUSTRY

Principal Investigators

  • Johan Rosman, MD, Ph.D · LCR Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02469467 on ClinicalTrials.gov